Stifel Nicolaus Issues Pessimistic Forecast for Elanco Animal Health (NYSE:ELAN) Stock Price

Elanco Animal Health (NYSE:ELAN) had its target price cut by equities researchers at Stifel Nicolaus from $15.00 to $13.00 in a report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective points to a potential upside of 57.69% from the stock’s current price.

Several other research analysts have also commented on the stock. Piper Sandler decreased their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, March 6th. Barclays lowered their target price on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. UBS Group cut their price target on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Finally, Morgan Stanley reduced their price objective on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Hold” and an average target price of $14.67.

Elanco Animal Health Stock Down 5.0 %

NYSE:ELAN opened at $8.24 on Monday. The stock has a 50-day simple moving average of $10.45 and a 200 day simple moving average of $11.96. Elanco Animal Health has a one year low of $8.03 and a one year high of $18.80. The company has a market capitalization of $4.09 billion, a price-to-earnings ratio of 20.61, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter last year, the firm posted $0.08 earnings per share. Elanco Animal Health’s revenue was down 1.4% compared to the same quarter last year. Sell-side analysts predict that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Insider Transactions at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius acquired 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were acquired at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the purchase, the director now directly owns 111,459 shares in the company, valued at $1,136,881.80. This trade represents a 9.86 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.57% of the company’s stock.

Hedge Funds Weigh In On Elanco Animal Health

A number of institutional investors and hedge funds have recently bought and sold shares of ELAN. SG Americas Securities LLC acquired a new stake in shares of Elanco Animal Health in the 1st quarter worth approximately $891,000. Yousif Capital Management LLC acquired a new stake in Elanco Animal Health in the first quarter worth approximately $119,000. Mitchell & Pahl Private Wealth LLC lifted its position in Elanco Animal Health by 4.0% in the first quarter. Mitchell & Pahl Private Wealth LLC now owns 45,489 shares of the company’s stock worth $478,000 after purchasing an additional 1,761 shares during the period. NBC Securities Inc. bought a new position in Elanco Animal Health during the 1st quarter valued at $40,000. Finally, Douglas Lane & Associates LLC increased its position in shares of Elanco Animal Health by 5.6% during the 1st quarter. Douglas Lane & Associates LLC now owns 3,895,190 shares of the company’s stock valued at $40,899,000 after purchasing an additional 205,241 shares during the period. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.